-
公开(公告)号：US20230326547A1
公开(公告)日：2023-10-12
申请号：US17980862
申请日：2022-11-04
Inventor： Mark YANDELL , Martin REESE , Chad HUFF , Hao HU , Marvin MOORE
IPC: G16B20/00
CPC classification number: G16B20/00
Abstract: Disclosed are methods for detecting and/or prioritizing phenotype-causing genomic variants and related software tools. The methods include genomic feature based analysis and can combine variant frequency information with sequence characteristics such as amino acid substation. The methods disclosed are useful in any genomics study; for example, rare and common disease gene discovery, tumor growth mutation detection, personalized medicine, agricultural analysis, and centennial analysis.
-
42.发明公开公开(公告)号：US20230310547A1
公开(公告)日：2023-10-05
申请号：US18145730
申请日：2022-12-22
Applicant: University of Utah Research Foundation
Inventor： TIANXIN YANG
IPC: A61K38/17
CPC classification number: A61K38/177
Abstract: Disclosed are methods of treating obesity or an obesity-related condition comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject that is obese or having an obesity-related condition. In some instances, obesity-related conditions can be, but are not limited to, steatosis, hyperglycemia, insulin resistance, chronic renal disease. Disclosed are methods of reducing body weight comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating fatty liver in a subject comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating a fluid and electrolyte disorder comprising administering an effective amount of sPRR to a subject diagnosed with a fluid and electrolyte disorder.
-
43.发明公开公开(公告)号：US20230309842A1
公开(公告)日：2023-10-05
申请号：US18022411
申请日：2021-08-21
Applicant: University of Utah Research Foundation
Inventor： Matthew ALEXANDER , Ramesh GRANDHI , Austin JOHNSON
IPC: A61B5/021 , A61B5/0215 , A61B17/12
CPC classification number: A61B5/02141 , A61B5/0215 , A61B17/12045 , A61B5/02233
Abstract: Catheter devices and methods are disclosed and described. A catheter device (100) can include a longitudinal lumen (104) and having a proximal end (104a) and a distal end (104b). The distal end (104b) is capable of insertion into at least the internal carotid artery. The catheter device (100) can include an occlusion balloon (120b) connected to the distal end (104b) and operable to occlude blood flow in a blood vessel (102) by inflation and deflation using a pressurization fluid. The catheter device (100) can include a pressure sensor (110b) associated with the distal end (104b) and operable to measure blood pressure data from at least one of a downstream (103b) and upstream (103a) location of the occlusion balloon (120b) and transmit the blood pressure data to a controller (150). The occlusion balloon (120b) can be operable to inflate or deflate based on inflation control information. The catheter device (100) can be used to treat cerebral thrombectomy in a subject.
-
公开(公告)号：US20230272479A1
公开(公告)日：2023-08-31
申请号：US18010580
申请日：2021-06-17
Applicant: University of Utah Research Foundation
Inventor： Jacob M. Winter , Jared Rutter
IPC: C12Q1/6886 , A61K31/69 , A61K38/07 , A61P35/00
CPC classification number: C12Q1/6886 , A61K31/69 , A61K38/07 , A61P35/00 , C12Q2600/156 , C12Q2600/106
Abstract: Disclosed are any of the methods or compositions herein. Disclosed are methods of treating a subject having cancer comprising administering a proteasome inhibitor to the subject having cancer, wherein the subject having cancer has a non-functional ATAD1 gene. Disclosed are methods of diagnosing and treating cancer, the method comprising: diagnosing a subject as being susceptible to treatment by a proteasome inhibitor; and administering a proteasome inhibitor to the subject.
-
公开(公告)号：US11708556B2
公开(公告)日：2023-07-25
申请号：US15520795
申请日：2015-10-20
Applicant: University of Utah Research Foundation
Inventor： Bruce K. Gale , Douglas T. Carrell , Kristin Murphy , Jim Hotaling , Jiyoung Son
CPC classification number: C12M47/04 , A61B17/435 , A61D19/00 , B01L3/502761 , C12M23/16 , C12N5/0612 , G01N30/0005 , B01L3/502738 , B01L2200/0652 , B01L2300/0816 , B01L2300/0864 , G01N2030/002
Abstract: A tissue sample processing system and associated methods is disclosed and described. The tissue sample processing system (100) can include a microfluidic separating system (110). The microfluidic separating system (110) can include a fluid channel to receive a carrier fluid (104) and a tissue sample (102), and a plurality of outlets. Flow of the carrier fluid (104) and the tissue sample (102) in the fluid channel can facilitate segregation of materials in the tissue sample (102) based on size into a plurality of size fractions, such that each one of the plurality of outlets receives a different size fraction of the materials in the tissue sample. In addition, the sample processing system (100) can comprise a cryopreservation system (120) associated with at least one of the plurality of outlets to freeze the material in the tissue sample (102) associated with the at least one of the plurality of outlets.
-
Patent Agency Ranking
公开(公告)号：US11678035B2
公开(公告)日：2023-06-13
申请号：US16753694
申请日：2018-10-05
Applicant: University of Utah Research Foundation
Inventor： Rajesh Menon , Ganghun Kim
IPC: H04N5/225
CPC classification number: H04N5/2258 , H04N5/2253 , H04N5/2254
Abstract: An imaging system that is translucent can be achieved by placing an image sensor (204) at one of more edges or periphery of a translucent window (202). A small fraction of light from the outside scene scatters off imperfections (218) in the translucent window (202) and reach the peripheral image sensor (204). Based on appropriate calibration of the response of point sources (206) from the outside scene, the full scene can be reconstructed computationally from the peripherally scattered light (210, 212). The technique can be extended to color, multi-spectral, light-field, 3D, and polarization selective imaging. Applications can include surveillance, imaging for autonomous agents, microscopy, etc.
-
公开(公告)号：US20230165976A1
公开(公告)日：2023-06-01
申请号：US17599979
申请日：2020-04-10
Applicant: University of Utah Research Foundation
Inventor： Brandi Williams , Gregory Hageman , Burt Timothy Richards , Osama Youssef
IPC: A61K48/00 , C12N15/11 , A61K31/7088 , C12N9/22
CPC classification number: A61K48/0066 , C12N15/11 , A61K31/7088 , C12N9/22 , C12N2310/20
Abstract: The invention provides compositions and methods for treatment of Chromosome 10-driven age-related macular degeneration, including gene therapy to increase HTRA1 expression in retinal pigmented epithelial cells in the eye.
-
公开(公告)号：US11660032B2
公开(公告)日：2023-05-30
申请号：US16811295
申请日：2020-03-06
Inventor： Natalie A. Silverton , Kai Kuck , Bradley J. Stringer , Spencer B. Shumway , Lars Lofgren
IPC: A61B5/20 , A61M25/10 , A61B5/1455 , A61B5/145 , A61B5/026
CPC classification number: A61B5/208 , A61B5/0261 , A61B5/14507 , A61B5/14552 , A61B5/14556 , A61B5/201 , A61M25/10 , A61B2560/0252 , A61M2205/0205
Abstract: An oxygen-sensing assembly for attachment to a urinary catheter may include a housing having a flow pathway extending between an inlet end and an outlet end thereof, an oxygen sensor in operable communication with the flow pathway of the housing, the oxygen sensor configured to detect oxygen levels of a fluid flowing through the flow pathway and a flowrate sensor configured to detect a flowrate of the fluid flowing through the flow pathway. A risk of acute kidney injury may be determined based on the mass flowrate of oxygen through the flow pathway, determined based on the detected oxygen levels and the flowrate of the fluid through the flow pathway. Related catheter assemblies and methods are also disclosed.
-
公开(公告)号：US20230158108A1
公开(公告)日：2023-05-25
申请号：US17923180
申请日：2021-05-04
Applicant: University of Utah Research Foundation
Inventor： Christian Con Yost , Joshua D. Schiffman
CPC classification number: A61K38/1709 , A61P29/00
Abstract: Disclosed are methods for treating neutrophil extracellular trap (NET) mediated inflammatory tissue damage in a patient having COVID-19, comprising administering to the patient having COVID-19 an effective amount of a pharmaceutical composition comprising a NET-inhibitory peptide (NIP) and a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the NET-mediated inflammatory tissue damage Disclosed are methods for inhibiting NET formation in a patient having COVID-19 comprising administering to the patient having COVID-19 an effective amount of a pharmaceutical composition comprising a NIP and a pharmaceutically acceptable carrier to substantially inhibit NET formation.
-
公开(公告)号：US20230146205A1
公开(公告)日：2023-05-11
申请号：US17981133
申请日：2022-11-04
Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventor： Joshua R. Malzahn , Eric G. Eddings
CPC classification number: C10B53/07 , C10B57/005 , C10B57/02
Abstract: Methods and systems for producing mesophasic (between liquid and solid phases) carbon materials from plastic waste. The method and system includes a 2-stage pyrolysis reactor, including first and second pyrolysis stages where a carbon feedstock material is subjected to pyrolysis. The first pyrolysis stage may subject the carbon feedstock material to pyrolysis at a first temperature in a range of 500° C. to 700° C., and the second pyrolysis stage may operate at a second temperature in a range of 800° C. to 1000° C., providing secondary gas phase reactions (SGR). A residence time of the carbon feedstock material in the reactor may be no more than 10 seconds. After pyrolysis and SGR, a sparging and thermal treatment stage may convert pyrolysis tar products to an anisotropic pitch product suitable for use in production of carbon fiber or bulk graphite for use in fabrication of graphite electrodes.
-
-
-
-
-
-
-
-
-
Search Results
1382
records
(took 0.034 seconds)
